Literature DB >> 8164106

Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virus.

J Polanec1, I Seppälä, S Rousseau, K Hedman.   

Abstract

Immunoassays have been recently developed that measure the avidity of IgG antibodies to complex microbial antigens and are suitable for serologic diagnosis of infectious diseases. In these avidity ELISAs, protein-denaturing agents are applied either as diluents of patient sera to prevent the immune complexing of IgG (diluting principle), or the preformed complexes are treated with the protein denaturants (eluting principle). We compared four protein denaturants previously used in such assays, in a diagnostic avidity ELISA for rubella IgG. Diethylamine, guanidine, thiocyanate, or urea were applied, by either principle at various concentrations, and thiocyanate, or urea were applied, by either principle at various concentrations, and thiocyanate at an optimum pH. Patient sera obtained recently after primary infection were distinguished from sera representing past rubella immunity by any protein denaturant tested by the eluting principle, which was superior to the diluting principle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164106     DOI: 10.1002/jcla.1860080105

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  15 in total

1.  Reliability of low-avidity IgG and of IgA in the diagnosis of primary infection by rubella virus with adaptation of a commercial test.

Authors:  J Gutiérrez; M J Rodríguez; F De Ory; G Piédrola; M C Maroto
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

3.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Clayton Harro; Ligia A Pinto
Journal:  Vaccine       Date:  2010-06-17       Impact factor: 3.641

5.  Comparison of different enzyme-linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies.

Authors:  Lenka Fialová; Milada Petráčková; Oliver Kuchař
Journal:  J Clin Lab Anal       Date:  2017-01-26       Impact factor: 2.352

6.  Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14.

Authors:  Hilde-Kari Guttormsen; Carol J Baker; Moon H Nahm; Lawrence C Paoletti; Susu M Zughaier; Morven S Edwards; Dennis L Kasper
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

7.  Development of fully automated determination of marker-specific immunoglobulin G (IgG) avidity based on the avidity competition assay format: application for Abbott Architect cytomegalovirus and Toxo IgG Avidity assays.

Authors:  Ingo Curdt; Gerald Praast; Eva Sickinger; Jan Schultess; Iris Herold; Hans Bertram Braun; Stephanie Bernhardt; Gregory T Maine; Darwin D Smith; Stephen Hsu; Heike M Christ; Dominick Pucci; Michael Hausmann; Jörg Herzogenrath
Journal:  J Clin Microbiol       Date:  2009-01-07       Impact factor: 5.948

8.  Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.

Authors:  J K Simon; R Wahid; M Maciel; W L Picking; K L Kotloff; M M Levine; M B Sztein
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

9.  BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.

Authors:  Federico Pratesi; Teresita Caruso; Davide Testa; Tiziano Tarpanelli; Alessandra Gentili; Davide Gioè; Paola Migliorini
Journal:  Vaccines (Basel)       Date:  2021-06-18

10.  Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections.

Authors:  Bengt Rönnberg; Åke Gustafsson; Olli Vapalahti; Petra Emmerich; Åke Lundkvist; Jonas Schmidt-Chanasit; Jonas Blomberg
Journal:  Med Microbiol Immunol       Date:  2017-08-29       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.